| Prasugrel | A P2Y12 platelet inhibitor used to reduce risk of thrombotic cardiovascular events in unstable angina or non-ST-elevation myocardial infarction (NSTEMI), and in patients with STEMI when managed with either primary or delayed PCI. |
| Eptifibatide | A peptide-based antagonist for glycoprotein IIb/IIIa used in the medical management of myocardial infarction and as an adjunct to percutaneous coronary intervention. |
| Tirofiban | A platelet aggregation inhibitor used to prevent thrombotic events in non-ST elevated acute coronary syndrome. |
| Dipyridamole | A phosphodiesterase inhibitor used to prevent postoperative thromboembolic events. |
| Ticlopidine | A platelet aggregation inhibitor used in the prevention of conditions associated with thrombi, such as stroke and transient ischemic attacks (TIA). |
| Ticagrelor | A P2Y12 platelet inhibitor used in patients with a history of myocardial infarction or with acute coronary syndrome (ACS) to prevent future myocardial infarction, stroke and cardiovascular death. |
| Cangrelor | A P2Y12 platelet receptor antagonist used during percutaneous coronary intervention to reduce the risk for periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST). |
| Clopidogrel | An antiplatelet agent used to prevent blood clots in peripheral vascular disease, coronary artery disease, and cerebrovascular disease. |
| Acetylsalicylic acid | A salicylate used to treat pain, fever, inflammation, migraines, and reducing the risk of major adverse cardiovascular events. |